AVRO
Closed
Avrobio Inc
1.4
0.0 (0.00%)
Last Update: 20 Jun 2024 23:04:00
Yesterday: 1.42
Day's Range: 1.38 - 1.44
Send
sign up or login to leave a comment!
When Written:
1
AVROBIO Inc. is a clinical-stage gene therapy company that develops gene therapies to treat rare genetic diseases. The company is headquartered in Cambridge, Massachusetts, and was founded in 2015. AVROBIO's gene therapies are designed to address the underlying genetic defects that cause these diseases, rather than just treating the symptoms. The company's lead product candidate is AVR-RD-01, which is being developed to treat Fabry disease, a rare genetic disorder that affects the kidneys, heart, and other organs. AVROBIO is also developing gene therapies for other rare genetic diseases, including Gaucher disease, cystinosis, and Pompe disease. The company has partnerships with academic institutions and industry partners to advance its gene therapy pipeline.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








